Search company, investor...

JeNaCell

jenacell.de

Founded Year

2012

Stage

Acquired | Acquired

Total Raised

$900K

About JeNaCell

JeNaCell is a specialist in the development and manufacture of biotechnology-derived nanocellulose with a well-defined design and a structure that can be controlled. Founded in 2012 as a spin-off of the Friedrich Schiller University Jena, the company provides customers with product solutions in the field of medicine, cosmetics, technology, and pharmaceutical. On August 2, 2021, JeNaCell was acquired by Evonik. The terms of the transaction were not disclosed.

Headquarters Location

Göschwitzer Str. 22

Jena, 07745,

Germany

+49 3641 - 23501 0

Missing: JeNaCell's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: JeNaCell's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing JeNaCell

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

JeNaCell is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

JeNaCell Patents

JeNaCell has filed 5 patents.

The 3 most popular patent topics include:

  • Polysaccharides
  • Cellulose
  • Coaxial connectors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/29/2020

12/20/2022

Skin care, Dosage forms, Drug delivery devices, Polysaccharides, Rare diseases

Grant

Application Date

6/29/2020

Grant Date

12/20/2022

Title

Related Topics

Skin care, Dosage forms, Drug delivery devices, Polysaccharides, Rare diseases

Status

Grant

Latest JeNaCell News

Evonik, Coopmed Devise Wound Dressing Distribution Deal

Oct 26, 2022

Coopmed will distribute epicite, which is made from biosynthetic cellulose, exclusively to the German market. The wound dressing epicite. Image courtesy of Evonik. Michael Barbella, Managing Editor10.26.22 Evonik has signed a distribution agreement with consulting and sales company Coopmed for the wound dressing epicite. Coopmed is now distributing epicite—made from biosynthetic cellulose—exclusively to the German market for chronic wound management. epicite is part of the portfolio of JeNaCell, a company based in Jena, Germany, which Evonik acquired in 2021 following prior investment. “We are excited to work with a highly experienced partner like Coopmed for the market development and distribution of epicite to advance the treatment of chronic wounds,” said Dana Kralisch, general manager of JeNaCell. “Together, we will work to make epicite® available to outpatients throughout Germany. We would like to thank all wound experts and professional users who supported us with case studies, practical advice and their personal experiences using the product.”   JeNaCell produces biosynthetic cellulose, a nature-identical material that is particularly suitable for wound cleansing and supporting the healing process of acute and chronic wounds due to its moist microclimate.1 Chronic wounds are wounds that do not heal even after several weeks. Typical reasons for their development are circulatory disorders, diabetes mellitus or a suppression of the immune system. In Germany, about 2.7 million people suffer from chronic wounds.2   “With epicite we can offer many outpatients a perfect alternative to hydrogels, which will no longer be covered by many health insurances in Germany from 2024,” said Hubertus Ruthmann, senior partner and co-founder of Coopmed. “Based on many years of clinical experience with epicite in burns, we are convinced that we can offer patients with chronic wounds an excellent product.”    JeNaCell originally emerged as a spin-off from Friedrich Schiller University in Jena, Germany. In 2017, the company launched epicite wound dressing as its first product. Other technologies developed by JeNaCell include soft tissue implants, transdermal release systems and dermatological applications. Evonik recognized JeNaCell's potential in 2015 and invested in the start-up through its own venture capital arm. Following the complete takeover, JeNaCell's portfolio was integrated into the Health Care business line of Evonik, expanding its portfolio of biomaterials, related services, and device manufacturing. References 1 Zahel P et al., Bacterial Cellulose—Adaptation of a Nature-Identical Material to the Needs of Advanced Chronic Wound Care, Pharmaceuticals 2022, 15, 683 2 Riedl S, Storck M: Versorgung von Patienten mit chronischen Wunden und Wundheilungsstörungen – eine Aufgabe für die Chirurgie. Passion Chirurgie. 2021 Januar/Februar; 11(01/02): Artikel 03_02.

JeNaCell Frequently Asked Questions (FAQ)

  • When was JeNaCell founded?

    JeNaCell was founded in 2012.

  • Where is JeNaCell's headquarters?

    JeNaCell's headquarters is located at Göschwitzer Str. 22, Jena.

  • What is JeNaCell's latest funding round?

    JeNaCell's latest funding round is Acquired.

  • How much did JeNaCell raise?

    JeNaCell raised a total of $900K.

  • Who are the investors of JeNaCell?

    Investors of JeNaCell include Evonik, High-Tech Grunderfonds, STIFT, Sparkasse Jena, bm-t beteiligungsmanagement thuringen and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.